Sun Pharma Q1 Results: Stock falls 3% from highs after US sales miss expectations

Sun Pharma’s Earnings before interest taxes depreciation and amortisation (EBITDA) increased to ₹4,417 crore, compared to street estimates of ₹4,255 crore. The figure turned out to be 3% higher than last fiscal’s ₹4,302 crore.

Leave a Reply

Your email address will not be published. Required fields are marked *